PD-L1 expression in head and neck squamous cell carcinoma and its clinical significance: A prospective observational study from a tertiary care centre.

Autor: Kilaru S; Department of Medical Oncology, IMS and SUM Hospital, SOA University, Bhubaneswar, Odisha, India., Panda SS; Department of Medical Oncology, IMS and SUM Hospital, SOA University, Bhubaneswar, Odisha, India., Moharana L; Department of Medical Oncology, IMS and SUM Hospital, SOA University, Bhubaneswar, Odisha, India., Mohapatra D; Department of Pathology, IMS and SUM Hospital, SOA University, Bhubaneswar, Odisha, India., Mohapatra SSG; Department of Radiology, IMS and SUM Hospital, SOA University, Bhubaneswar, Odisha, India., Panda A; Department of Radiology, IMS and SUM Hospital, SOA University, Bhubaneswar, Odisha, India., Kolluri S; Department of Medical Oncology, IMS and SUM Hospital, SOA University, Bhubaneswar, Odisha, India., Devaraj S; Department of Medical Oncology, IMS and SUM Hospital, SOA University, Bhubaneswar, Odisha, India., Kabi A; Department of Pathology, IMS and SUM Hospital, SOA University, Bhubaneswar, Odisha, India., Das B; Department of Medical Oncology, Sparsh Hospital and Critical care, Bhubaneswar, Odisha, India., Biswas G; Department of Medical Oncology, IMS and SUM Hospital, SOA University, Bhubaneswar, Odisha, India.; Department of Medical Oncology, Sparsh Hospital and Critical care, Bhubaneswar, Odisha, India.
Jazyk: angličtina
Zdroj: Journal of cancer research and therapeutics [J Cancer Res Ther] 2024 Jan 01; Vol. 20 (1), pp. 46-51. Date of Electronic Publication: 2023 May 02.
DOI: 10.4103/jcrt.jcrt_1239_22
Abstrakt: Background: Programmed Death Ligand 1 (PD-L1) expression in tumor cells contribute to tumor immunity and therapies directed against it, have shown encouraging results in recent years. As there is limited data on the significance of PD-L1 expression in Head and Neck Squamous Cell Carcinoma (HNSCC) from India, we aimed to study the PD-L1 expression and its relation with different clinic-pathological parameters in patients of HNSCC from a tertiary care center in Eastern India.
Methods: A prospective evaluation of HNSCC patients diagnosed and managed at our center over a period of two and half years, was performed. PD-L1 expression in formalin fixed-paraffin embedded tumor tissue specimens was measured using SP-263 (Ventana) and 22C3 (Dako). A PD-L1 expression of <1%, 1-19%, ≥20% were considered negative, low, and high expression, respectively, and was correlated with various parameters.
Results: A total of 71 patients (mean age 50.8 ± 13.3 years, 86% males) were diagnosed with HNSCC (buccal mucosa-28, tongue-22, rest of oral cavity-8, larynx-7, nasopharynx-6). The tumor was poorly differentiated in 12 (17%). PD-L1 positivity was seen in a total of 51 (71.8%) patients (1-19%:18, ≥20%:33). Thirty (85.7%) patients among those aged <50 years and 58.3% of those aged ≥50 years showed PD-L1 positivity which was significant (P = 0.01). There were no statistically significant differences in PD-L1 positivity with respect to gender, tobacco use, tumor grade as well as tumor and nodal stage. Median follow up duration was 18 months (range 3-31 months) and there was significant difference in overall survival among PD-L1 positive and negative groups (31 vs 24 months; log rank P = 0.03).
Conclusions: 72% of HNSCC patients in our cohort showed PD-L1 positivity and it was not associated with any patient demographic characteristics or aggressive pathological features. Positive PD-L1 expression may have a beneficial effect on overall survival in HNSCC.
(Copyright © 2023 Copyright: © 2023 Journal of Cancer Research and Therapeutics.)
Databáze: MEDLINE
Externí odkaz: